Bethany Torr, Institute of Cancer Research, London, UK, discusses the results of the BRCA-DIRECT study (NCT04842799), evaluating the digital service offering information on germline genetic testing for women with breast cancer, formulated to replace the standard of care telephone call that is currently available to patients. The study introduced a digital pathway for germline BRCA1, BRCA2, and PALB2 testing in women with breast cancer in the UK. Participants were randomized to receive information through a Genetic Counsellor (GC) telephone appointment or the BRCA-DIRECT web application. The results showed that uptake of genetic testing in the BRCA-DIRECT group was non-inferior to the GC group. Patient knowledge and anxiety levels were also comparable. Healthcare professionals found the digital pathway to be equivalent or superior to the standard of care. This approach demonstrates the feasibility and acceptability of a digital pathway for expanded genetic testing in breast oncology settings. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.